Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ProQR Therapeutics N.V.    PRQR   NL0010872495

PROQR THERAPEUTICS N.V.

(PRQR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
4.36(c) 4.46(c) 4.33(c) 4.49(c) 4.37(c) Last
178 735 239 726 870 774 390 714 125 809 Volume
+1.87% +2.29% -2.91% +3.70% -2.67% Change
More quotes
Financials (USD)
Sales 2020 10,8 M - -
Net income 2020 -53,0 M - -
Net Debt 2020 - - -
P/E ratio 2020 -4,08x
Yield 2020 -
Sales 2021 3,30 M - -
Net income 2021 -76,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,49x
Yield 2021 -
Capitalization 219 M 219 M -
Capi. / Sales 2020 20,3x
Capi. / Sales 2021 66,4x
Nbr of Employees -
Free-Float 90,0%
More Financials
Company
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic... 
More about the company
Notations Surperformance© of ProQR Therapeutics N.V.
Trading Rating : Investor Rating :
More Ratings
All news about PROQR THERAPEUTICS N.V.
01/07PROQR THERAPEUTICS N : Completes Sepofarsen Study Enrollment to Treat Vision Los..
MT
01/07ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatme..
GL
2020ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT ..
GL
2020ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
GL
2020ProQR Announces Third Quarter 2020 Operating and Financial Results
GL
2020ProQR Announces Virtual Presentations at American Academy of Ophthalmology (A..
GL
2020ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
GL
2020ProQR Announces Virtual Presentations at Scientific Conferences
GL
2020ProQR to Participate in Upcoming Investor Conferences
GL
2020ProQR Announces Second Quarter 2020 Operating and Financial Results
GL
2020ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal..
GL
2020ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement wi..
GL
2020ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen
GL
2020ProQR Announces Expert Perspectives Conference Call Series
GL
2020ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the..
GL
More news
News in other languages on PROQR THERAPEUTICS N.V.

- No features available -

More news
Chart PROQR THERAPEUTICS N.V.
Duration : Period :
ProQR Therapeutics N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROQR THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 21,67 $
Last Close Price 4,37 $
Spread / Highest target 655%
Spread / Average Target 396%
Spread / Lowest Target 243%
EPS Revisions
Managers and Directors
NameTitle
Daniel Anton de Boer Chief Executive Officer
Domenico Valerio Chairman-Supervisory Board
Smital Shah Chief Financial & Business Officer
Aniz Girach Chief Medical Officer
Jennifer Pluim Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PROQR THERAPEUTICS N.V.4.05%219
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458